PLAUR and cancer: As a result, the field of uPAR-based oncological imaging is progressing rapidly and, not surprisingly, various positron-emission tomography (PET)-based molecular imaging clinical trials are currently being conducted for diagnosing aggressive cancers and determining cancer aggressiveness (NCT02755675, NCT02945826, and NCT03307460) [13, 14].